Skip to content

Xencor

US · XNCR #2825 by market cap Listed 1970
33.26 -0.75 -2.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:51

Valuation each multiple against its own 5-year range

P/B ratio 4.97 Expensive vs history 100th percentile
5-year average 2.11 · #387 of 514 in Biotechnology
P/E ratio -23.78 Cheap vs history 10th percentile
5-year average -21.99 · forward -9.80
P/S ratio 13.88 Expensive vs history 83rd percentile
5-year average 9.36 · forward 26.70 · #195 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Xencor (XNCR) 2.50B -21.32 4.45 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value48.15 Economic moatNone UncertaintyVery High

Trading 44.8% below Morningstar's fair value estimate.

Fair value

Xencor Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 23% discount to our quantitative fair value estimate of $48.15 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 6.6 sits in the bottom 50% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

Conversely, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, ranks in the top 30% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:51:50 · For reference only, not investment advice and not tailored to your situation.

Xencor discussion 0 comments

Add a comment